Clinical Trials Browser

INDUSTRY × Uveal Melanoma × pembrolizumab × Clear all

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Phase 2 Completed

378 enrolled 15 charts 1 FDA

Uveal Melanoma, Melanoma

NCT05987332 2026-02-17

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Phase 2/3 Active not recruiting

Uveal Melanoma, Melanoma

NCT04130516 2025-12-18

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

Phase 1/2 Recruiting

DermatologicGastrointestinalThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

NCT06784648 2025-11-19

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Phase 1/2 Active not recruiting

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT03611868 2025-08-07

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Phase 1/2 Active not recruiting

DermatologicSarcoma

Uveal Melanoma, Melanoma, Neurofibrosarcoma

NCT04993677 2025-05-11

A Study of SEA-CD40 Given With Other Drugs in Cancers

Phase 2 Completed

77 enrolled 18 charts

DermatologicThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05576077 2025-03-10

STARLING

Phase 1 Terminated

BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms